Document is current
Any future updates will be listed below
-
Authors
Tang, Alison D. https://orcid.org/0000-0001-7125-0793
Soulette, Cameron M. https://orcid.org/0000-0001-8274-1838
van Baren, Marijke J.
Hart, Kevyn
Hrabeta-Robinson, Eva
Wu, Catherine J. https://orcid.org/0000-0002-3348-5054
Brooks, Angela N. https://orcid.org/0000-0002-7898-3073
-
Funding
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation
Pew Charitable Trusts
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5T32HG008345, R01HG010053)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM008646, 2R25GM058903)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Ford Foundation
Leukemia and Lymphoma Society
- License Information
-
More Information
Article History
Received: 24 September 2018
Accepted: 6 February 2020
First Online: 18 March 2020
Competing interests
: A.D.T. and A.N.B. have been reimbursed for travel, accommodation, and registration for conference sessions organized by Oxford Nanopore Technologies. C.J.W. is a co-founder of Neon Therapeutics, Inc and is a member of its scientific advisory board, and receives research funding from Pharmacyclics. All other authors have declared no competing interests.
